- Home
- TORO vs ALEC Comparison
TORO vs ALEC Comparison
Compare TORO & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TORO | ALEC |
|---|---|---|
| Founded | 2022 | 2013 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.5M | 167.6M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TORO | ALEC |
|---|---|---|
| Price | $6.10 | $2.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.83 |
| AVG Volume (30 Days) | 22.4K | ★ 1.4M |
| Earning Date | 04-15-2026 | 05-04-2026 |
| Dividend Yield | ★ 36.86% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $21,045,000.00 |
| Revenue This Year | N/A | $2.03 |
| Revenue Next Year | N/A | $29.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.64 | $1.09 |
| 52 Week High | $8.50 | $3.40 |
Technical Indicators
Market Signals| Indicator | TORO | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 72.65 | 65.30 |
| Support Level | $4.87 | $1.96 |
| Resistance Level | $8.50 | $2.64 |
| Average True Range (ATR) | 0.38 | 0.23 |
| MACD | 0.05 | 0.07 |
| Stochastic Oscillator | 74.02 | 78.50 |
Price Performance
Historical ComparisonAbout TORO Toro Corp.
Toro Corp is engaged in the acquisition, ownership, chartering, and operation of oceangoing tanker and LPG carrier vessels, providing seaborne transportation services for crude oil, refined petroleum products, and liquefied petroleum gas. The company operates through three segments: the Eco tanker segment, the Non-Eco tanker segment, and the LPG carrier segment. It generates the majority of its revenue from the LPG carrier segment.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.